Study register · detail
Clear benefit
GRADE
High
4 citations
Samplek = 14 Studien
Durationunclear
ControlPlacebo
EndpointNeuropathic pain score
Blindingdoppelblind
DesignSystematic Review
Key finding
Cannabinoids showed a statistically significant reduction in neuropathic pain with a mean difference of -0,67 on a 0-10 pain scale compared to placebo.
Summary
Systematic review on cannabinoids in peripheral neuropathy; k=14 RCTs identified. 13/14 studies (79%) showed statistically significant pain reduction. Meta-analysis across 7 studies: mean difference -0.67 [95% CI -0.89, -0.45] on 0-10 scale vs. placebo (p<0.001). Additional improvements in sleep, sensory symptoms and quality of life.
P
PopulationAdults with peripheral neuropathy and neuropathic pain, pooled from 14 RCTs
I
InterventionCannabinoids (various cannabis-based medicines)
C
ControlPlacebo
O
OutcomeSignificant pain reduction in 13/14 studies (93%); meta-analysis: mean difference -0,67 [95% CI: -0,89; -0,45] on 0–10 scale vs. placebo
Confidence in the evidence
High
The highest of four GRADE levels, the effect estimate is very reliable.
Quality profile
Sample size
★★★★★
Blinding
Double-blind
Effect size
Clear benefit
Citations / year
★★★★★
Authors
Share
Abstract
Purpose: Peripheral neuropathies are commonly occurring conditions that are chronic and debilitating for patients. Established nonsurgical treatments have yielded mixed and patient-dependent results. Although cannabinoids have demonstrated efficacy as a treatment for central neuropathic pain, the therapeutic potential of cannabis-based medications for the management of peripheral neuropathic pain caused by nerve injury, trauma, and other noncompressive etiologies has yet to be definitively established. This study aims to determine whether cannabinoids are a potentially effective treatment for pain and symptoms associated with peripheral neuropathy.
Methods: A systematic search was conducted by two independent reviewers across PubMed, Cochrane, Ovid Medline, and CINAHL to identify studies in accordance with the predetermined inclusion/exclusion criteria. Information regarding study design, medication, dosage, effect on neuropathic pain, and other related outcomes was extracted. Meta-analysis of pain scores was performed for seven studies, and descriptive statistics were used to summarize other study findings as appropriate.
Results: Of the 927 studies identified, 14 randomized controlled trials were included. Thirteen of 14 studies (79%) observed a statistically significant decrease in neuropathic pain score following treatment with a cannabinoid. Meta-analysis yielded a mean difference of -0.67 [-0.89, -0.45]) on a 0-10 scale compared with placebo. Improvements in secondary outcomes such as sleep, sensory symptoms, and quality of life were observed.
Conclusions: Our analysis of the literature shows that cannabis-based medicines may be effective in treating the pain and symptoms of peripheral neuropathy. These findings suggest the applicability of cannabis-based medicines for peripheral neuropathy.
Type Of Study/Level Of Evidence: Therapeutic IV.
The impediment to action advances action.